Search

Displaying results 871 - 880 of 2674 in total
  1. Target

    Corticotropin-releasing hormone receptor 2

    go.drugbank.com/bio_entities/BE0014244
    TargetHumans

    G protein-coupled receptor for CRH, UCN, UCN2 and UCN3 stress hormones, which plays a central role in whole body adaptation to stress (PubMed:11329063, PubMed:11416224, PubMed:20966082, PubMed:22689579

    Polypeptides: Corticotropin-releasing hormone receptor 2Synonyms: Corticotropin-releasing factor receptor 2
  2. Target

    Interleukin-10 receptor subunit alpha

    go.drugbank.com/bio_entities/BE0014391
    TargetHumans

    Cell surface receptor for the cytokine IL10 that participates in IL10-mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation.

    Polypeptides: Interleukin-10 receptor subunit alphaSynonyms: IL-10 receptor subunit alpha, Interleukin-10 receptor subunit 1
  3. Target

    G protein-coupled receptor 68

    go.drugbank.com/bio_entities/BE0014724
    TargetHumans

    The receptor is almost silent at pH 7.8 but fully activated at pH 6.8 (PubMed:12955148, PubMed:39753132). … Proton-sensing G protein-coupled receptor activated by extracellular pH, which is required to monitor pH changes and generate adaptive reactions (PubMed:12955148, PubMed:29677517, PubMed:32865988, PubMed

    Polypeptides: G protein-coupled receptor 68Synonyms: G protein-coupled receptor 12A, Ovarian cancer G protein-coupled receptor 1
  4. Target

    G protein-coupled receptor 84

    go.drugbank.com/bio_entities/BE0020007
    TargetHumans

    G protein-coupled receptor that responds endogenously to dietary fatty acids or nutrient, specifically medium-chain free fatty acid (FFA) with carbon chain lengths of C9 to C14. … In immune cells, functions as a pro-inflammatory receptor via 6-OAU and promotes the expression of pro-inflammatory mediators such as TNFalpha, IL-6 and IL-12B as well as stimulating chemotactic responses

    Polypeptides: G protein-coupled receptor 84Synonyms: Inflammation-related G protein-coupled receptor EX33
  5. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    Marstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology. It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anti...

  6. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA

  7. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    The FDA said it is keeping the black box in place at least until the results of the trial are announced. … This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor.

    Mixtures: Nra-varenicline, Nra-vareniclineCategories: Cholinergic Receptor Agonist
  8. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … [FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.

    Products: KETOCONAZOLE HRA, Ketoconazole Hra
  9. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    The active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine intestinal mucosa [FDA Label]. … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.

  10. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA). … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development